The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function

British Journal of Clinical Pharmacology

Volumn 49, Issue SUPPL. 1, 2000, Pages 21-26

  Everson, G ^a   Lasseter, K C ^b   Anderson, K E ^c   Bauer, L A ^d   Carithens Jr , R L ^d   Wilner, K D ^e   Johnson, A ^e   Anziano, R J ^e   Smolarek, T A ^e   Turncliff, R Z ^e  

^a UNIVERSITY OF COLORADO   (United States)

^b Clinical Pharmacology Associates Miami   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Hepatic impairment; Metabolism; Pharmacokinetics; Ziprasidone

Indexed keywords

PHENAZONE; ZIPRASIDONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; LIVER CIRRHOSIS; PRIORITY JOURNAL;

EID: 0034061638     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00149.x     Document Type: Article

References (14)

1. Wilner KD, Tensfeldt TG, Baris B, et al. Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br J Clin Pharmacol 2000; 49(Suppl. 1): 15S-20S.
2. Aweeka F, Jayesekara D, Morton M, et al. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. Br J Clin Pharmacol 2000; 49(Suppl. 1): 27S-33S.
3. Prakash C, Kamel A, Cui D, et al. Identification of the major human liver cytochrome P450 isoform responsible for the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol 2000; 49(Suppl. 1): 35S-42S.
4. Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding varices. Br J Surgery 1973; 60: 646-649.
5. Teunissen MWE, Meerburg van er Touen JE, Vermeulen NPE, et al. Automated HPLC determination of antipyrine and its main metabolites in plasma, saliva and urine including 4,4′-dihydroxyantipyrine. J Chromatogr Biomed Appl 1983; 278: 367-378.
6. Danhof M, deGroot van de vis Breimen DD. Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high pressure liquid chromatography and preliminary results in man. Pharmacology 1978; 18: 210-223.
7. Janiszewski JS, Fouda HG, Cole RO. Development and validation of a high-sensitivity assay for an antipsychotic agent, CP-88,059, with solid-phase extraction and narrow-bore high-performance liquid chromatography. J Chromatogr 1995; 668: 133-139.
8. Boudinot FD, Jusko WJ. Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis. J Pharm Sci 1984; 6: 774-780.
9. Engel G, Hofmann U, Heidemann H, et al. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalysing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine and norantipyrine formation. Clin Pharmacol Ther 1996; 59: 613-623.
10. Lown KS, Kolars JC, Thummel KE, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994; 22: 947-955.
11. Fromm MF, Busse D, Kroemer HK, et al. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 1996; 24: 976-801.
12. Kolars JC, Lown KS, Schmiedlin-Ren P, et al. CYP3A4 gene expression in gut epithelium. Pharmacogenetics 1994; 4: 247-259.
13. 1-acid glycoprotein: implications for binding of drugs. Ther Drug Monit 1986; 8: 259-293.
14. Snoeck E, Van Peer A, Sack M, et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology 1995; 122: 223-229.